

Table S4 Characteristics of studies included in the meta-analysis.

Trial number	Author's name	Publication year	Ethnicity	Type of clinical manifestations	Diagnostic time	Follow-up period	Dosage of tofacitinib	Measures of efficacy	Measures of safety
NCT00678210	Papp et al	2012	White, Asian, other	Plaque psoriasis	≥6 months	12 weeks	5 mg BID	PASI 75, PASI 90, PGA 0/1	Nasopharyngitis, URTI, Headache
NCT01241591	Bachelez et al	2015	White, Asian, other	Plaque psoriasis	≥12 months	12 weeks	5 mg/10 mg BID	PASI 75, PASI 90, PGA 0/1	Nasopharyngitis, URTI, Hypercholesterolemia, CPK elevation
NCT01276639	Papp et al	2015	White, Asian, other	Plaque psoriasis	≥12 months	12 weeks, 16 weeks	5 mg/10 mg BID	PASI 75, PASI 90, PGA 0/1	Nasopharyngitis, URTI, Hypercholesterolemia, CPK elevation, Headache
NCT01309737	Papp et al	2015	White, Asian, other	Plaque psoriasis	≥12 months	12 weeks, 16 weeks	5 mg/10 mg BID	PASI 75, PASI 90, PGA 0/1	Nasopharyngitis, URTI, Hypercholesterolemia, CPK elevation, Headache
NCT01815424	Zhang et al	2017	Asian	Plaque psoriasis	≥12 months	16 weeks	5 mg/10 mg BID	PASI 75, PASI 90, PGA 0/1	Nasopharyngitis, URTI, Hypercholesterolemia
NCT01882439	Gladman et al	2017	Asian	Psoriatic arthritis	≥6 months	12 weeks	5 mg/10 mg BID	PASI 75	Nasopharyngitis, URTI, Headache
NCT01877668	Mease et al	2017	White, other	Psoriatic arthritis	≥6 months	12 weeks	5 mg/10 mg BID	PASI 75	Nasopharyngitis, URTI, CPK elevation, Headache

BID, Twice-daily; PASI 75, ≥ 75% reduction in the Psoriasis Area and Severity Index score; PASI 90, ≥ 90% reduction in the PASI score; PGA 0/1, Physician's Global Assessment of "clear" or "almost clear"; URTI, Upper respiratory tract infection; CPK, Creatinine phosphokinase.